Company intelligence

SNGX

Soligenix, Inc. · NASDAQ · Healthcare

Price$0.37+0.44% · +$0.00

Market cap5.42MEquity value

P / E-0.3Trailing ratio

Volume145.3KLatest session

Market data

SNGX price chart

TradingView

Related signals

1 min delayed

Browse public SNGX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

SNGXDec 17, 2025+1.23% since signal

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix reports positive Phase 2a trial results for SGX302 in psoriasis. Improved gel formulation enhances application ease and patient tolerance. Marked improvements in treatment success metrics observed in trial participants. SGX302 potentially offers a non-carcinogenic treatment option for psoriasis lesions. SNGX stock is down 21.05% at $1.21 as of the publication.

View signal analysis

SNGXAug 18, 2025-28.02% since signal

Why Is Soligenix Stock Soaring On Monday?

SNGX stock surged after FDA granted orphan designation to dusquetide. Orphan drug designation ensures market exclusivity and regulatory benefits. Dusquetide shows efficacy in Behçet’s Disease with positive Phase 2a results. Up to one million people worldwide affected by Behçet’s Disease. SNGX stock rose 67.29% to $4.65 following the news.

View signal analysis

Research